Sutacimig
HMB-001-201
Phase 2 small_molecule active
Quick answer
Sutacimig for Congenital Factor VII Deficiency is a Phase 2 program (small_molecule) at Hemab Therapeutics Holdings with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Hemab Therapeutics Holdings
- Indication
- Congenital Factor VII Deficiency
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active